Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

OLMA Olema Pharmaceuticals

Watchlist
4.710
-0.030-0.63%
Close  01/27 16:00 ET
5.000
+0.290+6.16%
Post Mkt Price 01/27 17:51 ET
High
4.990
Open
4.680
Turnover
517.08K
Low
4.462
Pre Close
4.740
Volume
106.45K
Market Cap
190.55M
P/E(TTM)
Loss
52wk High
7.410
Shares
40.46M
P/E(Static)
Loss
52wk Low
2.000
Float Cap
92.51M
Bid/Ask %
-33.33%
Historical High
60.270
Shs Float
19.64M
Volume Ratio
0.40
Historical Low
2.000
Dividend TTM
--
Div Yield TTM
--
P/B
0.88
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.54%
Amplitude
11.13%
Avg Price
4.857
Lot Size
1
Float Cap
92.51M
Bid/Ask %
-33.33%
Historical High
60.270
Shs Float
19.64M
Volume Ratio
0.40
Historical Low
2.000
Dividend TTM
--
P/B
0.88
Dividend LFY
--
Turnover Ratio
0.54%
Amplitude
11.13%
Avg Price
4.857
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
CEO: Dr. Sean Bohen, M.D.,PhD
Market: NASDAQ
Listing Date: 11/19/2020
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist